Low Dose Naltrexone (LDN): A Novel Approach to Chronic Pain, Inflammation, and Recovery

What Is Low Dose Naltrexone

Naltrexone is a medication that has been used for decades at higher doses, typically 50 mg, for the treatment of opioid and alcohol use disorders. At these doses, it works by blocking opioid receptors, which reduces the reinforcing effects of addictive substances. Low dose naltrexone, usually defined as doses between 0.5 mg and 4.5 mg, works very differently. Instead of sustained opioid blockade, it produces a brief and partial receptor blockade that appears to trigger downstream regulatory effects in the nervous system and immune system.

This lower dose strategy has gained attention because it may influence chronic pain, inflammation, and recovery in ways that are not seen with traditional medications. While LDN is not FDA approved for these uses, it has developed a growing off-label role in conditions such as fibromyalgia, chronic pelvic pain, autoimmune disease, and other chronic inflammatory states.

How Low Dose Naltrexone Works

The mechanism of LDN is complex and still being actively studied. One of the primary theories is that short-term opioid receptor blockade leads to a rebound increase in endogenous endorphin production. This may help improve pain modulation and central nervous system signaling over time. In addition, LDN appears to have effects on microglia, which are immune cells within the central nervous system that play a key role in neuroinflammation.

By reducing microglial activation, LDN may help decrease the production of pro-inflammatory cytokines and excitatory signaling that contribute to chronic pain, fatigue, and hypersensitivity syndromes. This is particularly relevant in conditions where central sensitization plays a role, such as fibromyalgia, chronic pelvic pain, and some forms of post-viral or post-injury syndromes.

There is also evidence that LDN may influence toll-like receptor 4 signaling, which is involved in immune activation and inflammatory cascades. This provides a biologic framework for why LDN may have effects across a range of inflammatory and pain-related conditions rather than acting as a single-target drug.

Clinical Evidence for Chronic Pain and Inflammation

The clinical evidence for LDN is still developing, but several small randomized and controlled studies have shown encouraging results. In fibromyalgia, LDN has been associated with reductions in pain, fatigue, and overall symptom burden compared with placebo. These studies are limited by size, but the consistency of the signal has made LDN an area of ongoing research interest.

LDN has also been studied in conditions such as Crohn’s disease, multiple sclerosis, and complex regional pain syndrome, with some studies suggesting improvement in symptoms or inflammatory markers. In chronic pelvic pain, where central sensitization and neuroinflammation are often present, LDN is increasingly being used as part of a broader treatment strategy, although high-quality randomized data are still limited.

One of the key points is that LDN is not a direct analgesic in the way that opioids or NSAIDs are. Its effects are more gradual and regulatory, which means patients often notice improvement over weeks rather than hours or days.

LDN in Musculoskeletal and Pelvic Health and Rehabilitation

LDN is particularly interesting because many musculoskeletal and pelvic pain conditions involve a combination of peripheral tissue irritation, pelvic floor dysfunction, and central nervous system sensitization. This includes conditions such as chronic prostatitis, pelvic floor tension myalgia, interstitial cystitis, and certain forms of sexual pain.

LDN can be used as part of a multimodal treatment strategy that also includes pelvic floor physical therapy, neuromodulation techniques, behavioral interventions, and in some cases targeted medications. By addressing the neuroinflammatory component of pain, LDN may help reduce symptom intensity and improve tolerance to rehabilitation therapies.

Concussions

One of the more interesting emerging areas for low dose naltrexone is concussion and post-concussion symptoms. The biologic rationale is strong. After a concussion, one of the major drivers of persistent symptoms appears to be neuroinflammation and ongoing microglial activation in the brain. Low dose naltrexone is thought to reduce glial inflammatory signaling, in part through effects on toll-like receptor 4 and related immune pathways in the central nervous system. That mechanism has made it increasingly attractive as a possible adjunct in patients with persistent headaches, sensory sensitivity, brain fog, fatigue, and other symptoms that may reflect central neuroinflammation rather than only structural injury.  

What Patients Should Expect

LDN is typically started at a low dose, sometimes around 0.5-1.0mg, and gradually increased over several weeks to a target dose between 3 mg and 4.5 mg depending on response and tolerance. This slow titration helps minimize side effects and allows clinicians to find the most effective dose for each patient.

Side effects are generally mild but can include vivid dreams, sleep disturbance, headache, or gastrointestinal symptoms, especially during the early phase of treatment. These effects often improve with dose adjustments or timing changes. Because naltrexone blocks opioid receptors, it cannot be used concurrently with opioid medications.

Patients should understand that LDN is not an immediate pain reliever. It is a regulatory therapy that works over time. The goal is to improve baseline function, reduce symptom intensity, and support long-term recovery rather than provide rapid short-term relief.

A Better Way to Approach Chronic Pain and Inflammation

LDN represents a different way of thinking about chronic pain and inflammation. Instead of simply suppressing symptoms, it aims to modulate the underlying signaling pathways that drive persistent pain and dysfunction. This approach aligns well with a broader rehabilitation model that focuses on restoring normal physiology rather than just masking symptoms.

At The Performance Medicine Institute, LDN is used selectively as part of a comprehensive care plan that may include physical therapy, strength training, metabolic optimization, sleep improvement, and targeted medical therapies. The goal is not just to reduce pain, but to restore function and improve long-term health.

LDN is not appropriate for every patient, and the evidence is still evolving. But in the right clinical context, it can be a useful tool that complements a structured, evidence-based approach to care. If you are interested in finding out if LDN can be helpful for you, reach out and we'd be happy to discuss more.

References

Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2007;102(4):820-828.

Toljan K, Vrooman B. Low-Dose Naltrexone (LDN) - Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82.

Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-672.

Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: a randomized controlled trial. Arthritis Rheum. 2013;65(2):529-538.